



Universiteit
Leiden
The Netherlands

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies (vol 20, 25, 2020)

Bangs, M.E.; Kudrow, D.; Wang, S.F.; Oakes, T.M.; Terwindt, G.M.; Magis, D.; ... ; Stauffer, V.L.

Citation

Bangs, M. E., Kudrow, D., Wang, S. F., Oakes, T. M., Terwindt, G. M., Magis, D., ... Stauffer, V. L. (2020). Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies (vol 20, 25, 2020). *Bmc Neurology*, 20(1). doi:10.1186/s12883-020-01675-7

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](#)
Downloaded from: <https://hdl.handle.net/1887/3182719>

Note: To cite this publication please use the final published version (if applicable).

CORRECTION

Open Access



Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

Mark E. Bangs¹, David Kudrow², Shufang Wang¹, Tina M. Oakes¹, Gisela M. Terwindt³, Delphine Magis⁴, Laura Yunes-Medina¹ and Virginia L. Stauffer^{1*}

Correction to: *BMC Neurol*

<https://doi.org/10.1186/s12883-020-1609-7>

Following publication of the original article [1], the authors noticed an error in the values for 'Hypersensitivity SMQ' and 'Rash' in Table 7. The data presented for 'Hypersensitivity SMQ' and 'Rash' were inadvertently the events that were potentially hypersensitivity rather than the events that were likely hypersensitivity after medical review. The table legend and discussion of the data in the text were and are correct.

Author details

¹Eli Lilly and Company, Indianapolis, IN 46285, USA. ²California Medical Clinic for Headache, Santa Monica, CA, USA. ³Leiden University Medical Center, Leiden, The Netherlands. ⁴Neurology Dept and Pain Clinic (CMTD), CHR East Belgium, Verviers, Belgium.

Published online: 13 March 2020

Reference

1. Bangs ME, Kudrow D, Wang S, Oakes TM, Terwindt GM, Magis D, Yunes-Medina L, Stauffer VL. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. *BMC Neurol*. 2020;20:25 <https://doi.org/10.1186/s12883-020-1609-7>.

The original article can be found online at <https://doi.org/10.1186/s12883-020-1609-7>

* Correspondence: vstauffer@lilly.com; stauffer_virginia@lilly.com

¹Eli Lilly and Company, Indianapolis, IN 46285, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 7 Percentage of patients in integrated double-blind studies who experienced a hypersensitivity event^{a,b}

	Placebo N = 1451 n (%)	Galcanezumab	
		120 mg N = 705 n (%)	240 mg N = 730 n (%)
Hypersensitivity SMQ	40 (2.8)	34 (4.8) ^c	32 (4.4) ^c
Rash	15 (1.0)	5 (0.7)	7 (1.0)
Injection site rash	2 (0.1)	6 (0.9) ^c	4 (0.6)
Dermatitis contact	4 (0.3)	3 (0.4)	4 (0.6)
Rhinitis allergic	3 (0.2)	3 (0.4)	4 (0.6)
Hypersensitivity	0 (0.0)	3 (0.4) ^c	2 (0.3) ^c
Injection site hypersensitivity	0 (0.0)	1 (0.1)	3 (0.4) ^c
Dermatitis allergic	0 (0.0)	3 (0.4) ^c	0 (0.0)
Eczema	3 (0.2)	1 (0.1)	2 (0.3)
Rash pruritic	0 (0.0)	2 (0.3) ^c	1 (0.1)
Urticaria	5 (0.3)	2 (0.3)	1 (0.1)
Injection site urticaria	1 (0.1)	1 (0.1)	1 (0.1)
Rash generalized	1 (0.1)	1 (0.1)	1 (0.1)
Rash papulosquamous	0 (0.0)	1 (0.1)	1(0.1)
Dermatitis atopic	1 (0.1)	0 (0.0)	1(0.1)
Eye allergy	0 (0.0)	1 (0.1)	0 (0.0)
Pruritus allergic	0 (0.0)	1 (0.1)	0 (0.0)
Rash erythematous	1 (0.1)	0 (0.0)	1 (0.1)
Rash maculo-papular	1 (0.1)	1 (0.1)	0 (0.0)
Bronchospasm	1 (0.1)	0 (0.0)	0 (0.0)
Conjunctivitis allergic	1 (0.1)	0 (0.0)	0 (0.0)
Drug hypersensitivity	1 (0.1)	0 (0.0)	0 (0.0)

Abbreviations: *MedDRA* Medical Dictionary for Regulatory Activities, *N* number of patients in the analysis population, *n* number of patients within each specific category, *SMQ* standardized MedDRA query

^aThese are likely events per medical review

^bCategorized by narrow standardized MedDRA[®] (v.19.1) query search terms.

MedDRA[®], the certified Medical Dictionary for Regulatory Activities terminology, is the international medical terminology developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

^cIndicates a statistically significant difference ($P < 0.05$) compared with placebo